Vagal nerve stimulation using an NCP (Cyberonics) device has been suggested as a potential treatment for patients with epilepsy that has previously proven refractory. Ten patients in Northern Ireland have had this device implanted and been fully audited preand post-operatively. Twelve months post-implantation, five patients have demonstrated a greater than 50% reduction in seizure frequency. A statistical reduction in seizure severity of the ictal phase of the major seizures has also been shown. Improvement in the patients' overall quality of life has, however, not been demonstrated in parallel to seizure reduction.
INTRODUCTION
Preliminary results from clinical trials 1, 2 of vagal stimulation from implanted electrodes with a neurocybernetic prosthesis (NCP; Cyberonics) have given initial indications that this device may be effective in reducing complex partial seizures in patients who had previously proven to be refractory to drug therapy. A number of multi-centre randomized active controlled trials have also demonstrated the efficacy of this device in reducing seizure frequency in patients with partial onset seizures 3, 4 .
In Northern Ireland, to date, 15 patients have had the NCP (Cyberonics) device implanted. The first 10 patients to undergo implantation have now been followed up for periods in excess of 12 months. These patients have been carefully audited pre-and postoperatively.
SUBJECTS
All patients selected for the vagal nerve stimulation had previously proven to have refractory epilepsy of a partial onset. All had been exposed to every existing conventional and novel antiepileptic medication available on prescription. All 10 were continuing to take medication often in polytherapy. All 10 patients had also been previously assessed for their suitability for more definitive surgical intervention, e.g. temporal lobectomy and had been found unsuitable.
The first 10 patients implanted were nine males and one female. Patients were aged 16 to 54 years (mean: 32 years). Six patients had an associated (mild) learning disability. All 10 patients had complex partial seizures and nine also suffered from secondarily generalized tonic-clonic seizures. Seizure frequency, pre-operatively ranged from 5-52 seizures per month (mean: 15 seizures per month; median: 12 seizures per month). The duration of epilepsy ranged from 16 to 47 years (mean: 27 years). Patients were taking, and continued to take, for at least the first 12 months of the study, their regular medication. Cases were taking a range of one to three antiepileptic drugs per patient (mean: 2.5 antiepileptic drugs per patient).
In all cases a detailed baseline assessment had been carried out in the months prior to surgery. Patients were required to complete seizure diaries recording seizure frequency and type throughout the study period. Seizure severity scores using the Liverpool Seizure Severity Scale 5 were compiled at 3-monthly intervals. An assessment of quality of life utilizing the Rank Health Scale was completed pre-operatively and at 12 months post-implantation. Eight of the 10 patients completed these two questionnaires. Learning disability was the limiting factor in the other two cases. Patients were seen at regular intervals at outpatients following implantation. The milliampage output stimulus of the device was increased at each outpatient visit to the maximum tolerated. For the first 12 months the parameters chosen were those that had been used in the previously reported studies. The device was programmed to fire (ON) for 30 seconds and remain inactive (OFF) for 5 minutes.
For those patients who did not appear to respond after 12 months to the standard firing parameters, the device was changed to a rapid-cycle firing parameter. This firing pattern set the device to fire (ON) for 7 seconds and (OFF) for 30 seconds.
RESULTS

Seizure frequency and severity
Follow-up post-implantation has been for a mean of 18 months (range 12-36 months). Nine patients remain on the 30 seconds ON, 5 minutes OFF parameter. One patient at the time of completion of this study had been switched to the rapid-cycle sequence. The mean end output current was 2.5 milliamps (range: 1-3 milliamps). The percentage change in seizure frequency per patient at 12 months post-implantation compared with baseline is shown in Fig. 1 . Two patients had a small rise in seizure frequency, two remained unchanged, five of the 10 patients at this treatment interval demonstrated a greater than 50% reduction in seizure frequency over baseline.
Two patients demonstrated a greater than 80% reduction in seizure frequency. No patients became seizure free. The percentage change in seizure frequency of the group as a whole over time is shown in Fig. 2 . The overall percentage reduction in seizure frequency over time for the group as a whole was approximately 30%. This reduction appeared to be maintained over time, although the numbers at follow-up intervals fell due to different implantation times. Attempts to reduce drug load over time generally did not prove successful. Seizure severity scores were measured using the Liverpool Seizure Severity Scale. Eight patients completed this questionnaire. At 12 months there was a significant (P = 0.03, Wilcoxon signed ranks test) reduction in the ictal phase of the major seizures (Fig. 3) . This reduction correlated with subjective reports from patients and relatives of a reduction in seizure severity. There was, however, no reduction in the other seizure severity scores.
Adverse events
Adverse events were recorded at each outpatient follow-up visit. One patient reported post-operative hoarseness; this disappeared spontaneously after a few months. Transient hoarseness related to firing (ON) was common and was recorded in 5 of the 10 patients. Coughing, again transient and related to firing (ON), was also reported in two patients. Both of these symptoms were transient and tended to wear off in the few days succeeding an increase in the output current. No cognitive or other effects were reported. One patient died during follow-up; this patient had had the device for in excess of 12 months. There had been no recent manipulation in his output current. It was reported by his parents that he had had a seizure and had subsequently been found dead in bed. A full autopsy was performed. The NCP device was found to be working normally. His death was attributed to a sudden unexpected death in epilepsy (SUDEP). 
Quality of life measures
Patients were asked directly how they related their health at 12 months to how they had been prior to the implantation of the vagal nerve stimulator. The overall scores suggested that they regarded their health subjectively as about the same as before the device had been implanted. On a linear scale patients (n = 8) were asked to rate their quality of life: from the best possible quality of life to worst possibility of life. The results at 12 months were identical to those obtained at baseline. Patients were asked about limitations to home, social and work activities. There was no reduction in the limitations reported at 12 months compared to baseline (n = 8).
DISCUSSION
Vagal nerve stimulation is becoming increasingly available throughout North America and the UK as a potential treatment for epilepsy that has previously prove refractory to both medical and surgical interventions. A theoretical basis for its efficacy exists and earlier multi-centre trials have demonstrated this efficacy. Its utilization as a standard and accepted treatment within the NHS, however, remains controversial. Each of the patients presented in this study was provided with individual funding from their relevant health board.
The results from our audit of these patients is very much in line with similar studies carried out elsewhere. An overall reduction in seizure frequency across the group of 30% is of the order demonstrated in other similar studies 3, 4 . Such a reduction in seizure frequency may appear small, yet this level of reduction in seizure frequency is similar to that demonstrated by all of the newer antiepileptics drugs in their clinical trials. No patients in this group became seizure free, although two had a greater than 80% reduction in seizure frequency. At this time, however, there is no method of differentiating responders from non-responders preoperatively.
The spectrum of adverse effects seen with this mode of therapy are entirely different to those seen with antiepileptic drugs for which cognitive and be-havioural effects are most common. The effects reported in this study and others largely reflect upon the direct stimulus applied to the left vagal nerve and were generally transient. The device was generally well tolerated. This may suggest advantage in the treatment of patients with learning disability in particular, as in these patients, who often demonstrate quite refractory epilepsy, cognitive and behavioural effects of medication often prove limiting factors.
One patient in this study group died. His death was attributed, after post-mortem, to SUDEP. Sudden unexpected death is a recognized complication of epilepsy 6 . Although relatively uncommon, those recognized at greatest risk are young people with severe and uncontrolled epilepsy. Previous studies 7 have addressed the possible effects of vagal nerve stimulation on gastric acid secretion and on cardiac rhythm with no significant effects being demonstrated.
Despite recorded reduction in seizure frequency and subjective reports of reduction in seizure severity, no improvement in quality of life was demonstrated using the measures chosen. This may reflect upon the relative insensitivity of these measures or upon the fact that quality of life and seizure frequency do not bear a linear relationship.
Cost implications need also to be considered. Each implantable device costs around £5000, plus there is the cost of surgery. The battery will last for about 5 years, depending on usage, and then need to be replaced, again at surgery. The initial cost has had the effect of limiting the use of this treatment technique, yet given the annual cost of the newer antiepileptic drugs (approx. £800-£1500 per year) and the not dissimilar results on seizure frequency, vagal nerve stimulation does not compare unfavourably. Further evidence of the effects on overall quality of life, particularly in the longer term, for patients offered this treatment is, however, required.
